NCT01046903View on ClinicalTrials.gov

An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®

CompletedOBSERVATIONAL
Enrollment

503

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Venous Thromboembolism
Interventions
DRUG

Fragmin® (Dalteparin Sodium)

Administered per prescribing physician

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01046903 - An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® | Biotech Hunter | Biotech Hunter